<DOC>
	<DOCNO>NCT01962636</DOCNO>
	<brief_summary>This treatment guideline unrelated umbilical cord blood transplant ( UCBT ) use myeloablative preparative regimen treatment hematological disease , include , limited acute leukemia . The myeloablative preparative regimen consist cyclophosphamide ( CY ) , fludarabine ( FLU ) fractionate total body irradiation ( TBI ) .</brief_summary>
	<brief_title>Umbilical Cord Blood Transplantation Using Myeloablative Preparative Regimen Hematological Diseases</brief_title>
	<detailed_description>This study collect routine clinical data UCBT use unrelated single double UCB unit alternative , non-HLA-matched stem cell source patient hematological disease . - data collection transplant preparative therapy consist treatment chemotherapeutic regimen total body irradiation . - data collection umbilical cord blood selection infusion . - data collection standard supportive disease transplant relate care . Pre- post-transplant medication , UCB selection infusion , supportive care , follow-up accord current University Minnesota BMT guideline . An average 18 patient expect treated protocol per year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Leukemia , Prolymphocytic</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Plasma Cell</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Hematologic Diseases</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>Eligible Disease Status Acute Myeloid Leukemia ( AML ) : high risk CR1 ( evidence precede MDS , high risk cytogenetics , ≥ 2 cycle obtain CR , erythroblastic megakaryocytic leukemia ; CR2+ . All patient must CR defined hematological recovery , AND &lt; 5 % blast light microscopy within bone marrow cellularity ≥15 % . Very high risk pediatric patient AML : Patients &lt; 21 year , however , eligible ( M2 marrow ) &lt; 25 % blast marrow fail one cycle chemotherapy . Acute Lymphocytic Leukemia ( ALL ) : high risk CR1 define cytogenetics ( ( 9 ; 22 ) , ( 1:19 ) , ( 4 ; 11 ) , MLL rearrangement , hypodiploidy , IKZF1 abnormality ) , DNA index &lt; 0.81 , &gt; 1 cycle obtain CR presence minimal residual disease ( MRD ) . Patients CR2+ eligible . All patient must CR defined hematological recovery , AND &lt; 5 % blast light microscopy within bone marrow cellularity ≥15 % . Very high risk pediatric patient ALL : patient &lt; 21 year also consider high risk CR1 M2 M3 marrow day 42 initiation induction M3 marrow end induction . They eligible achieved complete remission . Chronic Myelogenous Leukemia exclude refractory blast crisis : To eligible first chronic phase ( CP1 ) patient must fail intolerant imatinib mesylate . Plasma Cell Leukemia initial therapy , achieve least partial remission Advanced Myelofibrosis Myelodysplasia ( MDS ) IPSS INT2 High Risk ( i.e . RAEB , RAEBt ) Refractory Anemia severe pancytopenia high risk cytogenetics : Blasts must &lt; 10 % representative bone marrow aspirate morphology . Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma ( CLL/SLL ) , Marginal Zone BCell Lymphoma Follicular Lymphoma eligible disease progression/relapse within 12 achieve partial complete remission . Patients remission last &gt; 12 month , eligible least two prior therapy . Patients bulky disease ( nodal mass great 5 cm ) consider debulking chemotherapy transplant . Lymphoplasmacytic Lymphoma , MantleCell Lymphoma , Prolymphocytic Leukemia eligible initial therapy CR1+ PR1+ . Large Cell NHL &gt; CR2/ &gt; PR2 : Patients CR2/PR2 initial short remission ( &lt; 6 month ) eligible . Lymphoblastic Lymphoma , Burkitt 's Lymphoma , highgrade NHL initial therapy stage III/IV CR1/PR1 progression stage I/II &lt; 1 year . Multiple Myeloma beyond PR2 : Patients chromosome 13 abnormality , first response last less 6 month , β2 microglobulin &gt; 3 mg/L , may consider protocol initial therapy . Myeloproliferative Syndromes Availability suitable UCB unit ( ) 0 55 year Voluntary write consent ( adult parental/guardian ) previous irradiation precludes safe administration TBI Radiation Oncology evaluate patient previous radiation therapy chemotherapy refractory large cell high grade NHL ( ie progressive disease &gt; 2 salvage regimen ) ≤ 18 year old , prior myeloablative transplant within last 6 month . If &gt; 18 year old prior myeloablative allotransplant autologous transplant extensive prior therapy include &gt; 12 month alkylator therapy &gt; 6 month alkylator therapy extensive radiation pregnant breastfeeding HIV positive</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Umbilical Cord Transplant</keyword>
	<keyword>Acute Myeloid Leukemia ( AML )</keyword>
	<keyword>Acute Lymphocytic Leukemia ( ALL )</keyword>
	<keyword>Chronic Myelogenous Leukemia</keyword>
	<keyword>Plasma Cell Leukemia</keyword>
	<keyword>Myelofibrosis</keyword>
	<keyword>Myelodysplasia</keyword>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>Small Lymphocytic Lymphoma</keyword>
	<keyword>Marginal Zone B-Cell Lymphoma</keyword>
	<keyword>Follicular Lymphoma</keyword>
	<keyword>Lymphoplasmacytic Lymphoma</keyword>
	<keyword>Mantle-Cell Lymphoma</keyword>
	<keyword>Prolymphocytic Leukemia</keyword>
	<keyword>Large Cell Non-Hodgkin Lymphoma</keyword>
	<keyword>Lymphoblastic Lymphoma</keyword>
	<keyword>Burkitt 's Lymphoma</keyword>
	<keyword>Non-Hodgkin Lymphoma</keyword>
	<keyword>Multiple Myeloma</keyword>
</DOC>